DR5

• DR5 (Death Receptor 5) is a cell surface receptor that plays a critical role in apoptosis, or programmed cell death.
• It is a member of the TNF receptor superfamily and is also known as TRAIL-R2 or Apo2.
• The primary DR5 receptor function is to bind to its ligand, TRAIL, initiating a signaling cascade.
• The DR5 pathway explanation involves the formation of the Death-Inducing Signaling Complex (DISC) and the activation of caspases.
• DR5 is of significant interest in cancer research due to its ability to induce apoptosis preferentially in many cancer cells.

What is DR5 (Death Receptor 5)?

DR5 (Death Receptor 5) is a transmembrane protein that belongs to the tumor necrosis factor (TNF) receptor superfamily. It is also known by several other names, including TRAIL-R2 (TNF-related apoptosis-inducing ligand receptor 2) and Apo2. As a cell surface receptor, DR5 is strategically positioned to receive external signals that can trigger apoptosis, a highly regulated process of cell suicide essential for development, tissue homeostasis, and the removal of damaged or unwanted cells.

The DR5 protein definition describes it as having an extracellular domain responsible for ligand binding, a transmembrane domain anchoring it to the cell membrane, and an intracellular death domain. This death domain is crucial for transmitting apoptotic signals into the cell’s interior. DR5’s presence and activity are vital for the body’s natural defense mechanisms, particularly in suppressing the proliferation of potentially harmful cells, such as those with oncogenic mutations.

Dysregulation of DR5 expression or function has been observed in various diseases, including cancer, where its apoptotic signaling can be evaded by malignant cells. This makes DR5 a significant target for research aimed at restoring or enhancing programmed cell death in pathological conditions.

DR5 Receptor Function and Signaling Pathway

The primary DR5 receptor function is to initiate apoptosis upon binding to its specific ligand, TRAIL (TNF-related apoptosis-inducing ligand). TRAIL is a protein that can selectively induce programmed cell death in many cancer cells while often sparing normal, healthy cells. This selective action makes the TRAIL/DR5 pathway a compelling area of study for cancer therapies.

The DR5 pathway explanation begins when TRAIL binds to DR5 on the cell surface. This binding event causes DR5 receptors to cluster together, forming trimers. This trimerization is a critical step that enables the recruitment of intracellular adapter proteins, most notably FADD (Fas-associated death domain protein), to the death domain of DR5. This assembly leads to the formation of a multiprotein complex known as the Death-Inducing Signaling Complex (DISC).

Within the DISC, FADD recruits and activates initiator caspases, such as pro-caspase-8 and pro-caspase-10. These initiator caspases then undergo autocatalytic cleavage and activation. Once activated, they cleave and activate downstream effector caspases, primarily caspase-3 and caspase-7. These effector caspases are the “executioners” of apoptosis, responsible for cleaving numerous cellular substrates, leading to the characteristic morphological and biochemical changes associated with programmed cell death, such as DNA fragmentation, chromatin condensation, and cell shrinkage.

Key steps in the DR5 signaling pathway include:

• TRAIL ligand binds to DR5 receptors on the cell surface.
• DR5 receptors trimerize, leading to the recruitment of FADD.
• Formation of the Death-Inducing Signaling Complex (DISC).
• Activation of initiator caspases (e.g., caspase-8).
• Cleavage and activation of effector caspases (e.g., caspase-3, caspase-7).
• Execution of apoptosis through the degradation of cellular components.

Understanding this intricate pathway provides insights into how cells regulate their survival and death, offering potential avenues for therapeutic intervention, particularly in oncology, by targeting DR5 to re-sensitize cancer cells to apoptosis.